TREATMENT
Prior anti-EGFR therapy affects HER2-targeted treatment outcomes — ESMO Open
An integrated analysis of the TRIUMPH and MyPathway studies examined how prior treatment with anti-EGFR (epidermal growth factor receptor) therapy affects the effectiveness of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer. The study also explored the role of baseline circulating tumor DNA profiling to identify resistance mutations that might predict treatment response.
What this means
If your tumor is HER2-amplified, your treatment history and baseline genetic testing may help predict whether HER2-targeted therapy will work for you. Ask your oncologist about comprehensive molecular profiling.